Smartwatch Biometrics in the Electronic Medical Record: Time for a New Vital Sign? Before this clinical optimization process can start, the new first-in-class drug needs to be developed and approved.

Smartwatch Biometrics in the Electronic Medical Record: Time for a New Vital Sign? The following represents disclosure information provided by authors of this manuscript. All relationships are ...

Combination of Osimertinib and Vascular Endothelial Growth Factor Receptor Inhibitors for EGFR-Mutated Non–Small Cell Lung Cancer: Old or New Regimen? Clinical trials frequently include multiple end ...

View all available purchase options and get full access to this article. The following represents disclosure information provided by authors of this manuscript. All relationships are considered ...